Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico

Journal of Addiction Medicine

Volumn 1, Issue 3, 2007, Pages 126-132

  Garcia, Carmen Albizu ^a   Correa, Glorimar Caraballo ^a   Viver, Adriana D Hernandez ^a   Kinlock, Timothy W ^b,c   Gordon, Michael S ^b   Avila, Cristobal Antron ^d   Reyes, Ivette Colón ^d   Schwartz, Robert P ^b,e  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^b FRIENDS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF BALTIMORE   (United States)

^d Department of Correction and Rehabilitation   (Argentina)

^e Open Society Institute Baltimore   (United States)

Author keywords

Buprenorphine; Drug abuse treatment; Prisoners

Indexed keywords

EID: 68449100499     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e31814b8880     Document Type: Article

References (46)

1. Office of National Drug Control Policy. Drug Facts - Heroin. Washington, DC: Executive Office of the President, ONDCP; 2007.
2. Chaiken JM. Correctional Population of the United States, 1997. Washington, DC: Department of Justice; 2000.
3. Karberg JC, James DJ. Substance Dependence, Abuse, and Treatment of Jail Inmates, 2002. Washington, D.C.: National Institute of Justice, Bureau of Justice Statistics; 2005, NIJ Publication No. 209588.
4. Brown BS, Needle RH. Modifying the process of treatment to meet the threat of AIDS. Int J Addict. 1994;13 29:1739-1752. (Pubitemid 24361259)
5. Inciardi JA, McBride DC, Surratt HS. The heroin street addict: profiling a national population. In: Inciardi JA, Harrison L, eds. Heroin in the Age of Crack-Cocaine. Thousand Oaks, CA: Sage; 1998:31-50.
6. Smith-Rohrberg D, Bruce RD, Altice FL. Research note-Review of correction-based therapy for opiate-dependent patients: implications for buprenorphine treatment among correctional populations. J Drug Issues. 2004;34:451-480. (Pubitemid 38856418)
7. Rich JD, Boutwell AE, Shield DC, et al. Attitudes and practices regarding the use of methadone in U.S. state and federal prisons. J Urban Health. 2005;82:411-419. Available at: http://jurban.oxfordjournals.org/cgi/content/ abstract/jti072v. Accessed January 22, 2007. (Pubitemid 41191560)
8. Lines R., Stöver H., Kroll C., et al. HIV/AIDS Prevention, Care, Treatment and Support in Prison Settings: A Framework for an Effective National Response. New York: United Nations Office on Drugs and Crime, World Health Organization, Joint United Nations Programme on HIV/AIDS; 2006.
9. Belenko S, Peugh J. Estimating drug treatment needs among state prison inmates. Drug Alcohol Depend. 2005;77:269-281. (Pubitemid 40283529)
10. Pallone NJ, Hennessy JJ. To punish or to treat: substance abuse within the context of oscillating attitudes toward correctional rehabilitation. J Offender Rehab. 2003;37:1-26. (Pubitemid 37457714)
11. Mears DP, Winterfield L, Hunsaker J, et al. Drug Treatment in the Criminal Justice System: The Current State of Knowledge. Washington, D.C.: The Urban Institute; 2003.
12. Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer-Verlag; 1991.
13. Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000;67:347-364.
14. Platt J, Widman M, Lidz V, et al. Methadone maintenance treatment: its development and effectiveness after 30 years. In: Inciardi JA, Harrison LD, eds. Heroin in the Age of Crack-Cocaine. Thousand Oaks, CA: Sage; 1998:160-187.
15. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-oftreatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6:1049-1056. (Pubitemid 23239778)
16. Zarick GC, Barnet PG, Brandeau ML. HIV transmission and the costeffectiveness of methadone maintenance. Am J Public Health. 2000;90: 1-12.
17. Kinlock TW, Battjes RJ, Schwartz RP. A novel opioid maintenance program for prisoners: preliminary findings. J Subst Abuse Treat. 2002; 22:141-147. (Pubitemid 34597218)
18. Magura S, Rosenblum A, Lewis C, et al. The effectiveness of in-jail methadone maintenance. J Drug Issues. 1993;23:75-99.
19. Amass L, Bickel WK, Higgins ST, et al. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci. 1994;54:1215-1228. (Pubitemid 24107403)
20. Fischer G, Gombas W, Eder H, et al. Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction. 1999; 94:1337-1347. (Pubitemid 29433792)
21. Johnson RE, McCagh JC. Buprenorphine and naloxone for heroin dependence. Curr Psychiatry Rep. 2000;2:519-526.
22. Strain EC. Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. Clin J Pain. 2002;18:S14-S27. (Pubitemid 34815391)
23. Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2003;(2):CD002209.
24. Walsh SL, Preston KL, Stitzer ML, et al. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55:569-580. (Pubitemid 24192243)
25. Walsh SL, Preston KL, Bigelow GE, et al. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther. 1995;274:361-372.
26. Fudala PJ, Bridge TP, Herbert S, et al. Buprenorphine/Naloxone Collaborative Study Group. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-958. (Pubitemid 37064768)
27. Montoya ID, Gorelick DA, Preston KL, et al. Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharmacol Ther. 2004;75:34-48.
28. Kinlock TW, Schwartz RP, Gordon MS. The significance of interagency collaboration in developing opioid agonist programs for inmates. Corrections Compendium. 2005;30:28-30.
29. Senese JD, Kalinich DB. Activities and rehabilitation programs for offenders. In: Stojkovic S, Lovell R, eds. Corrections: An Introduction. 2nd ed. Cincinnati: Anderson; 1997:199-235.
30. Tims FM, Leukefeld CG. The challenge of drug abuse treatment in prisons and jails. NIDA Res Monogr. 1992;118:1-7. (Pubitemid 23078462)
31. Center for Disease Control. HIV/AIDS among Hispanics. CDC HIV/ AIDS Fact Sheet. 2006:1-6.
32. Deren S, Kang SY, Colon HM, et al. HIV incidence among high-risk Puerto Rican drug users: a comparison of East Harlem, New York, and Bayamon, Puerto Rico. J Acquir Immune Defic Syndr. 2004;36:1067-1074. (Pubitemid 38989373)
33. Andia JF, Deren S, Kang SY, et al. Residential status and HIV risk behaviors among Puerto Rican drug injectors in New York and Puerto Rico. Am J Drug Alcohol Abuse. 2001;27:719-735. (Pubitemid 33064019)
34. Heimer R, Catania H, Newman RG, et al. Methadone maintenance in prison: evaluation of a pilot program in Puerto Rico. Drug Alcohol Depend. 2006;83:122-129. (Pubitemid 43795476)
35. Albizu-García C, Román L, Luis R-B, et al. Estudio de Necesidades de Tratamiento para el Uso de Sustancias y la Prevención de VIH y Hepatitis B/C en las Prisiones de Puerto Rico. Report submitted to the Department of Corrections and Rehabilitation, Goverment of Pueto Rico, San Juan; 2005.
36. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, D.C.: American Psychiatric Association; 1994.
37. Johnson ES, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70:S59-S77. (Pubitemid 36556061)
38. Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J Psychoactive Drugs. 2003;35:253-259. (Pubitemid 36927370)
39. McLellan AT, Luborsky L, Cacciola JS, et al. New data from the ASI, reliability and validity in three centers. J Nerv Ment Dis. 1985;173:412-423. (Pubitemid 15068966)
40. Maddux JF, Desmond DP. Careers of Opioid Users [Praeger Studies on Issues and Research in Substance Abuse]. New York: Praeger; 1981.
41. Nurco DN, Stephenson P, Hanlon TE. Contemporary issues in drug abuse treatment linkage with self-help groups. NIDA Res Monogr. 1991;106:338-348.
42. Pani PP, Maremmani I, Piratsu R, et al. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend. 2000;60:39-50. (Pubitemid 30255984)
43. Strain EC, Stitzer ML, Liebson IA, et al. Buprenorphine versus methadone in the treatment of opioid-dependent cocaine users. Psychopharmacology. 1994;116:401-406. (Pubitemid 24374238)
44. Tomasino VA, Swanson AJ, Nolan J, et al. The Key Extended Entry Program (KEEP): a methadone treatment program for opiate-dependent inmates. Mt Sinai J Med. 2001;68:14-20. (Pubitemid 32063464)
45. Bamberger MR, Rugh J, Mabry L. Realización de Evaluaciones de Impacto de Calidad con Limitaciones de Presupuesto, Tiempo e Información. Washington, DC: Banco Internacional de Reconstrucción y Fomento/Banco Mundial; 2006.
46. Simpson DD, Knight K. Criminal Justice Treatment Evaluation Meeting II. Austin, TX: Center for Substance Abuse Treatment (CSAT) 1993